低剂量纳武单抗新辅助化疗导致非小细胞肺癌的完全病理反应。

IF 0.7 Q4 ONCOLOGY

Indian Journal of Surgical Oncology Pub Date : 2025-06-01 Epub Date: 2024-12-06 DOI:10.1007/s13193-024-02148-w

Prasanth Penumadu, Prasanth Ganesan, Dhanapathi Halanaik

{"title":"低剂量纳武单抗新辅助化疗导致非小细胞肺癌的完全病理反应。","authors":"Prasanth Penumadu, Prasanth Ganesan, Dhanapathi Halanaik","doi":"10.1007/s13193-024-02148-w","DOIUrl":null,"url":null,"abstract":"Lung cancer is the second most commonly diagnosed cancer worldwide and the most common cause of mortality. Locally advanced non-small cell carcinoma is treated with multimodality treatment. Neoadjuvant chemotherapy with or without immunotherapy is known to have a maximal response and improves outcomes in stage III lung cancers. Immunotherapy is not affordable in mid and low-socioeconomic-income countries. Here we report a 69-year-old gentleman treated with neoadjuvant low-dose nivolumab (LDNiv) with chemotherapy followed by surgery and it shows a complete pathological response. LDNiv could be an economical option and could be explored in future prospective studies.","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"16 3","pages":"813-815"},"PeriodicalIF":0.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267761/pdf/","citationCount":"0","resultStr":"{\"title\":\"Neoadjuvant Chemotherapy with Low-Dose Nivolumab Leading to Complete Pathological Response in Non-small Cell Lung Carcinoma.\",\"authors\":\"Prasanth Penumadu, Prasanth Ganesan, Dhanapathi Halanaik\",\"doi\":\"10.1007/s13193-024-02148-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lung cancer is the second most commonly diagnosed cancer worldwide and the most common cause of mortality. Locally advanced non-small cell carcinoma is treated with multimodality treatment. Neoadjuvant chemotherapy with or without immunotherapy is known to have a maximal response and improves outcomes in stage III lung cancers. Immunotherapy is not affordable in mid and low-socioeconomic-income countries. Here we report a 69-year-old gentleman treated with neoadjuvant low-dose nivolumab (LDNiv) with chemotherapy followed by surgery and it shows a complete pathological response. LDNiv could be an economical option and could be explored in future prospective studies.\",\"PeriodicalId\":46707,\"journal\":{\"name\":\"Indian Journal of Surgical Oncology\",\"volume\":\"16 3\",\"pages\":\"813-815\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267761/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Surgical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13193-024-02148-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13193-024-02148-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/6 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

肺癌是世界上第二大最常见的癌症，也是最常见的死亡原因。局部晚期非小细胞癌采用多模式治疗。新辅助化疗加或不加免疫治疗对III期肺癌有最大的疗效和改善预后。在中低收入社会经济收入国家，人们负担不起免疫疗法。在这里，我们报告了一位69岁的男士，接受新辅助低剂量纳沃单抗（LDNiv）化疗后手术治疗，并显示出完全的病理反应。LDNiv可能是一种经济的选择，可以在未来的前瞻性研究中进行探索。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Neoadjuvant Chemotherapy with Low-Dose Nivolumab Leading to Complete Pathological Response in Non-small Cell Lung Carcinoma.

Lung cancer is the second most commonly diagnosed cancer worldwide and the most common cause of mortality. Locally advanced non-small cell carcinoma is treated with multimodality treatment. Neoadjuvant chemotherapy with or without immunotherapy is known to have a maximal response and improves outcomes in stage III lung cancers. Immunotherapy is not affordable in mid and low-socioeconomic-income countries. Here we report a 69-year-old gentleman treated with neoadjuvant low-dose nivolumab (LDNiv) with chemotherapy followed by surgery and it shows a complete pathological response. LDNiv could be an economical option and could be explored in future prospective studies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Surgical Oncology ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

190

期刊介绍： The Indian Journal of Surgical Oncology aims to encourage and promote clinical and research activities pertaining to Surgical Oncology. It also aims to bring in the concept of multidisciplinary team approach in management of various cancers. The Journal would publish original article, point of technique, review article, case report, letter to editor, profiles of eminent teachers, surgeons and instititions - a short (up to 500 words) of the Cancer Institutions, departments, and oncologist, who founded new departments.